VY1706, an IV-delivered tau silencing gene therapy that has shown up to 73% knockdown of tau mRNA in non-human primates following a single IV dose and is advancing towards IND in 2026.

Firefly Aerospace files for IPO on Nasdaq, aiming to fund expansion. Learn about their lunar success, market growth, and ...

Secondary marketplace for private securities EquityZen is out with a note on Q2 activity. The company stated that Circle's successful initial public offering ...

Demand for Big Data services is increasing. Palantir, a leader in the field, should benefit. Here are the forecasts and price ...

After a couple years in a slump, initial public offerings have rebounded in 2025. Arnaud Blanchard, global co-head of equity capital markets at Morgan Stanley, joins us to discuss how IPOs from ...

Arnaud Blanchard, global head of equity capital markets at Morgan Stanley, joins WSJ’s Take On the Week to discuss how recent ...

Texas based Firefly Aerospace has filed for a US IPO after landing a NASA backed spacecraft on the Moon, positioning itself ...

In a Friday filing with the U.S. Securities and Exchange Commission, the company that landed on the moon in March announced ...

Firefly Aerospace, backed by AE Industrial Partners, announces a 10% revenue growth forecast for 2024, signaling positive momentum in the space and defense sector as it prepares for its initial public ...

Firefly is heading into the initial public offering with $176.9 million in cash and cash equivalents. And while it has ...

Funding to North American startups surged in the first half of 2025, fueled by investor enthusiasm around artificial ...

Voyager Technologies (VOYG) stock is set to garner retail attention on Monday after Jefferies initiated coverage for the ...